Staten Island, New York 10305

  • Brain and Central Nervous System Tumors


RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells in patients with primary or advanced glioma. PURPOSE: Clinical trial to study the effectiveness of biological therapy with interleukin-2 and lymphokine-activated killer cells in treating patients who have primary, recurrent, or refractory malignant glioma.

Study summary:

OBJECTIVES: - Confirm the antitumor efficacy of intracavitary interleukin-2 plus autologous lymphokine-activated killer cells in patients with primary, recurrent or refractory malignant gliomas. - Determine whether the induction of a regional, intracavitary, eosinophilia is a prognosticator of response to immunotherapy and long term survival in these patients. OUTLINE: Patients receive cytoreductive tumor surgery and/or biopsy and implantation of intracavitary Ommaya reservoir prior to therapy induction. Patients undergo outpatient leukapheresis on day -4 or -5, and cells are incubated ex vivo with interleukin-2 (IL-2). Lymphokine-activated killer (LAK) cells and IL-2 are infused on day 1. Bolus infusions of low-dose IL-2 are administered on days 3, 5, 8, 10, and 12, followed by a rest period on days 13-24. The course is repeated on day 25 starting with leukapheresis. Therapy courses are repeated for up to 1 year for stable disease or response to therapy. Maintenance doses repeat every 4-6 months thereafter. Disease restaging is done every 8-12 weeks. PROJECTED ACCRUAL: A total of 30 patients per year will be enrolled.


DISEASE CHARACTERISTICS: - Histologically or radiographically proven primary, recurrent, or refractory malignant gliomas (glioblastoma, anaplastic astrocytoma, and mixed anaplastic glioma) - Must be a candidate for neurosurgical biopsy or tumor debulking PATIENT CHARACTERISTICS: Age: - 18 and over Performance Status: - Karnofsky 60-100% Life Expectancy: - Greater than 4 months Hematopoietic: - Granulocytes greater than 1,500/mm^3 - Platelet count greater than 50,000/mm^3 - PT and PTT within normal limits Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal Renal: - Creatinine less than 1.5 mg/dL - Creatinine clearance greater than 60 mL/min Cardiovascular: - No congestive heart failure - No coronary artery disease - No serious cardiac arrhythmias - No prior myocardial infarction Pulmonary: - No major pulmonary problems Other: - No history of neurologic disease (except related to brain tumor) - No psychosis - No impaired cognitive function - No significant concurrent medical illness - No active infection requiring antibiotic therapy - Not pregnant - Negative pregnancy test - Fertile patients must use effective contraception - Adequate peripheral veins to permit leukapheresis, or placement of indwelling central vascular access device - No hepatitis B or C - HIV negative - No prior autoimmune disease - Allergy to gentamicin is allowed PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 6 weeks since prior immunotherapy and recovered - No concurrent immunotherapy Chemotherapy: - At least 4 weeks since prior chemotherapy (6 weeks for carmustine) and recovered - No concurrent chemotherapy Endocrine therapy: - Reduction or elimination of corticosteroids - Not greater than 0.15 mg/kg/day dexamethasone equivalent Radiotherapy: - At least 6 weeks since prior radiotherapy and recovered - No concurrent radiotherapy Surgery: - Prior surgery is allowed Other: - Concurrent therapy with acetaminophen, anticonvulsant agents, and headache pain medications is allowed



Primary Contact:

Study Chair
Roberta L. Hayes, PhD
Immune Therapy, LLC

Backup Contact:


Location Contact:

Staten Island, New York 10305
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.